Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals

Area of Science:

• Neurology
• Endocrinology
• Public Health

Background:

• Vitamin D sufficiency is linked to reduced multiple sclerosis (MS) activity, including relapses and MRI lesions.
• Current randomized controlled trials (RCTs) on vitamin D supplementation in MS yield inconclusive results.
• Experts advocate for routine vitamin D monitoring and supplementation in MS patients.

Purpose of the Study:

• To assess vitamin D status and supplementation practices among MS patients and healthcare professionals.
• To identify factors influencing vitamin D levels and supplementation adherence in MS patients.
• To evaluate the real-world vitamin D supplementation landscape in a clinical setting for MS.

Main Methods:

• An observational study involving 139 MS patients on disease-modifying therapy.
• Standardized questionnaires assessed vitamin D supplementation, influencing factors (education, sun exposure, smoking, obesity), and professional practices.
• Comparison of patient-reported data with baseline and 12-month serum vitamin D levels.

Main Results:

• 74.1% of MS patients reported vitamin D supplementation (cholecalciferol).
• Only 43.69% achieved optimal serum vitamin D levels (30-50 ng/mL).
• Absence of physician recommendation was the primary barrier to supplementation; 4000 IU daily was the most common prescribed dose. No adverse effects were noted.

Conclusions:

• While vitamin D status in MS patients is improving compared to the general population, a significant portion remains deficient or insufficient.
• Physician recommendation is crucial for effective vitamin D supplementation adherence in MS patients.
• Further research is needed to clarify optimal vitamin D dosing and its therapeutic role in MS management.